高樹庚，1966年生，籍貫山東，胸外科專家，腫瘤醫院副院長，主任醫師，博士生導師。1984年考入山東醫科大學臨床醫學專業，1989年獲得學士學位。1995年在中國協和醫科大學腫瘤學專業攻讀碩士學位，從事胸部腫瘤相關研究。2002年在中國協和醫科大學腫瘤學專業攻讀博士學位，從事胸部腫瘤臨床和轉化研究。2011年進入北京協和醫學院腫瘤研究所進行博士后研究工作，主要從事胸部腫瘤相關研究。1995年升為主治醫師。2003年為副主任醫師，2008年為主任醫師。

肺癌微創外科治療，早期非小細胞肺癌術式的創新及改進；局部晚期非小細胞肺癌新輔助治療模式構建；探索基于外周血ctDNA改變在肺癌復發轉移預測中的應用及其相關機制，推動基礎研究的臨床轉化。

爆草黑丝美女|韩国19禁无遮挡啪啪无码网站|91精品国产自产精品男人的天堂|sm鞭打高潮喷水抽搐调教玩弄|果冻在线|日本大尺度吃奶呻吟视频|久久久久黄片|北条麻妃av免费观看|中文字幕一区二区人妻|亚洲最大天堂无码精品区,日韩 欧美 国产精品,国产肉丝袜在线观看,最爽无遮挡行房视频,成人H视频在线观看,糖心vlog冉冉,蜜桃产品一二三产区

1. Guo W#, Zhou B#, Yang Z#, Liu X, Huai Q, Guo L, Xue X, Tan F, Li Y, Xue Q, Gao S*, He J. Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma. EBioMedicine. 2022 Oct;84:104281. (IF=11.205)

2. Zhou B#, Bie F#, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhao J*, Gao S*. RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer. EBioMedicine. 2022 Oct;84:104268. (IF=11.205)

3. Qiu B#, Ji Y#, Zhang F, Bai G, Xue Q, Polaczek M, Tosi D, Koike T, Gao S*, He J. Outcomes and experience of anatomical partial lobectomy. J Thorac Cardiovasc Surg. 2022 Sep;164(3):637-647.e1. (IF=6.439)

4. Guo W#, Chen X, Liu R, Liang N, Ma Q, Bao H, Xu X, Wu X, Yang S, Shao Y, Tan F, Xue Q, Gao S*, He J. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine. 2022 Jul;81:104131. (IF=11.205)

5. Zhang F#, Guo W#, Zhou B#, Wang S, Li N, Qiu B, Lv F, Zhao L, Li J, Shao K, Xue Q, Gao S*, He J. Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2022 Jul;17(7):909-920. (IF=20.121)

6. Zhou B#, Zang R, Zhang M, Song P, Liu L, Bie F, Peng Y, Bai G, Gao S*. Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study. EBioMedicine. 2022 Apr;78:103951. (IF=11.205)

7. Wang S#, Yuan P#, Mao B#, Li N, Ying J, Tao X, Tang W, Zhang L, Geng X, Zhang F, Xue Q, Wu L, Zhang H*, Gao S*, He J. Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. NPJ Precis Oncol. 2022 Jan 13;6(1):2. (IF=10.092)

8. Qiu B#, Guo W#, Zhang F, Lv F, Ji Y, Peng Y, Chen X, Bao H, Xu Y, Shao Y, Tan F, Xue Q, Gao S*, He J. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021 Nov 19;12(1):6770. (IF=17.694)

9. Yang Z#, Xu J, Li L, Li R, Wang Y, Tian Y, Guo W, Wang Z, Tan F, Ying J, Jiao Y, Gao S*, Wang J*, Gao Y*, He J*. Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nat Commun. 2020 Sep 28;11(1):4878. (IF=14.919)

10. Gao S#, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, Shao K, Lei W, Wang D, Lv F, Zhao L, Zhang F, Zhao Z, Su K, Tan F, Gao Y, Sun N, Wu D, Yu Y, Ling Y, Wang Z, Duan C, Tang W, Zhang L, He S, Wu N, Wang J, He J*. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020 May;15(5):816-826. (IF=15.609, ESI)